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Summary Apoptosis is a mode of cell death with characteristic structural features. These appear to result
from a set of discrete cellular events that are regulated by gene expression. Oncogenesis and oncosuppressor
genes are involved in this regulation. The role of c-myc is of particular interest, as it can act as a bivalent
regulator, determining either cell proliferation or apoptosis, depending on whether free movement around the
cell cycle is supported (by growth factors) or is limited by growth factor deprivation or treatment with other
cycle-blocking agents. In vivo, c-myc expression may be associated with a 'high-turnover' state in which cell
proliferation and apoptosis co-exist. Certain other oncogenes (e.g. ras, bcl-2) rescue cells from susceptibility to
apoptosis and so convert this high-turnover state into rapid population expansion. One role of the oncosupp-
ressor gene p53 may be to initiate apoptosis by causing G 1/S arrest in cells expressing c-myc. Some aspects of
resistance and sensitivity to chemotherapeutic agents can be explained on the basis of movement between the
population-expansion and the high-turnover states, perhaps through modulation of the expression of these and
other genes.
Apoptosis is a mode of cell death in which single cells are
deleted in the midst of living tissue. The term derives from a
Greek word used for the dropping off of leaves from trees. It
is characterised by structural changes that appear with great
fidelity in cells of widely different lineage, and presumably
represent a pleiotropic effector response (Kerr et al., 1972;
Wyllie et al., 1980; Arends & Wyllie, 1991). Apoptosis
accounts for most or all of the programmed death responsi-
ble for tissue modelling in vertebrate development, for the
cell loss that accompanies atrophy of adult tissues following
endocrine and other stimuli, and - at least in some tissues -
for the physiological death of cells in the course of normal
tissue turnover. The extensive deletion of cells of the B and T
lineages during negative selection in the immune response is
effected by apoptosis as is a proportion of the deaths of the
target cells of cell-mediated immune killing. Apoptosis occurs
widely in tumours, although it is not the only mode of death
adopted by tumour cells. It is often claimed that apoptosis is
the most significant component of the well-established con-
tinuous cell loss of most tumours, although quantitative data
to prove this are few (Sarraf & Bowen, 1988; Moore, 1987).
Irradiation, chemotherapy and the appropriate hormone
therapy all induce apoptosis in tumour cells. High doses of
irradiation and chemotherapy may also cause cell destruction
by other means (Searle et al., 1975; Dyson et al., 1986;
Szende et al., 1989; Eastman, 1990; Lennon et al., 1990;
Kyprianou et al., 1990; Kyprianou et al., 1991a,b; Marti-
kainen et al., 1991).
The morphological changes in apoptosis have been exten-
sively reviewed elsewhere (Kerr et al., 1972; Wyllie et al.,
1980; Kerr et al., 1987; Arends et al., 1990). Affected cells
shrink in volume, lose contact with their neighbours and lose
specialised surface elements such as microvilli and cell-cell
junctions. Time lapse studies have shown that these changes
occur rapidly and are accompanied by extraordinary surface
convolution and then the explosion of the cell into a series of
membrane-bounded, condensed apoptotic bodies. The endo-
plasmic reticulum dilates and a series of crater-like cavities
appear where the dilated cisternae fuse with the cell surface.
Otherwise, cytoplasmic organelles are largely intact. Initially,
and in contrast to cells dying by other means (e.g. necrosis),
mitochondria are normal in structure. The most outstanding
internal structural changes, however, occur in the nucleus.
Chromatin condenses into dense granular caps under the
nuclear membrane. Adjacent to these, nuclear pores are
absent. The nucleolus dissociates to leave a shower of
osmiophilic particles near the centre of the nucleus and the
bare fibrillar centre, which usually lies close to the peripheral
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condensed chromatin. Apoptotic cells do not induce an
inflammatory reaction, even when present in large numbers,
but they are targets of immediate phagocytosis, either by
macrophages already present nearby, or by other adjacent
viable cells. Within these, the compacted organelles and con-
densed chromatin of the apoptotic cells may be visible for a
few hours but eventually reduce to large nondescript
lysosomal residual bodies.
The effector mechanisms of apoptosis are still only incom-
pletely understood. The nuclear changes are caused by
activation of an endogenous calcium-magnesium sensitive
nuclease (Arends et al., 1990; Wyllie, 1980) which has not yet
been fully characterised. This cleaves chromatin between
nucleosomes, reducing the DNA of apoptotic cells to a series
of fragments, integer size multiples of 180-200 base pairs,
and thus producing a characteristic 'ladder' on agarose gel
electrophoresis.
The swift phagocytosis is the result of recognition by the
phagocytic cell of new molecular structures revealed on the
surface of the apoptotic cell. Recognition of apoptotic rodent
thymocytes can be blocked in vitro by N-acetyl glucosamine
and its dimer N,N'-diacetyl chitobiose, suggesting that a
component of the recognition signal may be a glycan rich in
exposed N-acetyl glucosamine residues (Duvall et al., 1985).
The vitronectin receptor of human macrophages is responsi-
ble for binding apoptotic human neutrophils (Savill et al.,
1990). The distinctive recognition pathway used by macro-
phages for binding apoptotic neutrophils may represent a
control point in the physiological termination of the acute
inflammatory reaction (Savill et al., 1989).
Many apoptotic cells express a new transglutaminase
activity that cross-links cytoplasmic proteins (Fesus et al.,
1989; Piacentini et al., 1991; Fesus et al., 1991). Some of the
shrinkage and distortion ofcontour of apoptotic cells may be
attributable to activation of this enzyme, but the dramatic
step-like increase in buoyant density shown by cells as they
enter apoptosis (Wyllie & Morris, 1982) must be due in
addition to net movement of fluid out of the dying cell. A
possible mechanism to account for this profound fluid shift
(responsible for loss of a third to a half of cell's volume
within a few minutes) is inhibition of the sodium-potassium-
chloride cotransporter system (Wilcock & Hickman, 1988).
The cellular triggers that initiate this pleiotropic response
have proved elusive. Shortly before onset of the chromatin
changes, at least in some cell types, free cytosolic calcium
rises to sustained, but moderate levels of around 800nM
(McConkeyet al., 1989a). This appears to be important for
the rest of the process, as blockade of calcium movement by
pharmacological means can inhibit apoptosis. It is not
known whether the sources of the calcium is external to the
cell or internal (for example from mitochondria), although
'." Macmillan Press Ltd., 1993 Br. J. Cancer (1993), 67, 205-208206 A.H. WYLLIE
this might have important implications for regulation. One
type of surface receptor molecule (APO-1,fas) appears to be
particularly involved in the triggering of apoptosis in some
cell types including leukaemic cell lines (Trauth et al., 1989;
Itoh et al., 1991). T-lymphocytes provide an example of how
single receptor-ligand interactions can lead to strikingly
different cellular responses. In the CD4 +, CD8 + immature
cortical thymocyte, ligands that occupy the T-cell receptor
initiate apoptosis, whereas in mature, post-thymic T-cells
they initiate entry to S-phase (Smith et al., 1989). Perhaps in
a similar way, TNF can trigger apoptosis in appropriate cell
types (Kyprianou et al., 1991a; Laster et al., 1988), although
in other circumstances it may act as a growth factor.
In several circumstances, blockade of protein and RNA
synthesis inhibits apoptosis (Wyllie et al., 1984), but cyclo-
heximide does not block - and indeed may initiate - apop-
tosis in some cell types. New transcription of genes that may
be triggers for apoptosis has been sought for by a candidate
gene strategy. There is a cascade-like induction of c-fos,
c-myc and hsp-70 in regressing prostate, for example (But-
tyan et al., 1988), and TGFP1 is induced during regression of
a hormone-sensitive breast carcinoma cell line (Kyprianou et
al., 1991b), but it is difficult from experiments of this type to
be certain that the new transcripts are integral to apoptosis
as opposed to other (perhaps abortive) stress responses.
Subtractive hybridisation has also been used to identify
genes whose transcription is uniquely associated with apop-
tosis. Several candidates are now known. Regressing
secretory epithelia in mammary and prostatic glands trans-
cribe a gene coding for a highly sulphated cell surface glyco-
protein with complement-inhibitory properties (TRPM-2)
(Monpetit et al., 1986; Buttyan et al., 1989), and several new
transcripts appear in apoptotic lymphocytes (Owens et al.,
1991). The roles of all of these interesting new molecules
have still to be established.
Regulatory genes influence cellular susceptibility to enter
apoptosis. Some of these have been identified and are already
familiar as oncogenes and oncosuppressor genes. At present,
there are convincing data relating to c-myc, bcl-2, p53 and
ras.
Expression of c-myc is of particular interest, as it seems to
determine either continuous proliferation or apoptosis,
depending on the availability of critical growth factors (Evan
et al., 1992). Cultured immortalised fibroblasts respond to
the addition of serum growth factors by entering the pro-
liferation cycle, and this is preceded by and apparently
dependent upon transcription of c-myc. On withdrawal of
serum growth factors, c-myc is down-regulated and the cells
revert to a growth-arrested state in which they may remain
viable for many weeks. In cells modified to express c-myc
constitutively, however, the absence of serum growth factors
is not accompanied by growth arrest. Instead, the cells
remain in cycle - and some may successfully complete DNA
and cellular replication - whilst substantial numbers die by
apoptosis. This effect of serum starvation can be produced by
other interventions that blockade some step in the prolifera-
tion cycle (for example leucine deprivation, thymidine-
induced S-phase arrest or treatment with topo-isomerase II
inhibitor (Bertrand et al., 1991; Fanidi et al., 1992)). Thus
c-myc expression and the availability of critical growth fac-
tors (of which IGF-1 appears to be the most significant in
fibroblasts) delineate three extreme cell states - growth arrest
(c-myc off, growth factors absent), population expansion (c-
myc on, growth factors present), and apoptosis (c-myc on,
growth factors oft). Study of cultured cells suggests the
existence of an intermediate high turnover state in which
susceptibility to apoptosis is high despite the fact that some
cells may be competent to enter the proliferation cycle (Dive
& Wyllie, 1992). Quantitative as well as qualitative considera-
tion may determine cell transitions between these states.
Some cellular proto-oncogenes appear to 'rescue' cells
from the high turnover state into the population expansion
state. Amongst these is bcl-2 (Hockenberry et al., 1990;
Nunez et al., 1990; Bissonnette et al., 1992; Fanidi et al.,
1992). An elegant demonstration of this is the resistance to
apoptosis of cortical thymocytes in which bcl-2 is engineered
for constitutive expression (Sentman et al., 1991; Strasser et
al., 1991). Such cells fail to undergo apoptosis in response to
a wide variety of stimuli to which normal thymocytes are
sensitive. Activation of bcl-2 is not unique in rescuing cells
from apoptosis. High expression of the mutated ras
oncogenes (Wyllie et al., 1987) and exposure to many growth
factors can have the same effect (Williams et al., 1990; Koury
& Bondurant, 1990) perhaps in a cell type dependent way.
Expression of wild type p53 appears to have the opposite
effect, inducing apoptosis in susceptible cells (Yonish-Rouach
et al., 1991). Wild-type p53 is known to cause temporary GI
arrest in some cell types (Kastan et al., 1991) and it is thus
possible that this arrest co-operates with endogenous c-myc
expression to initiate apoptosis.
It is not clear how these regulatory genes influence suscep-
tibility to apoptosis. One obvious mechanisms would be the
induction or depletion of the effector proteins discussed ear-
lier. In support of this, endogenous endonuclease activity is
readily demonstrated in the nuclei of fibroblasts that con-
stitutively express c-myc, but is absent from cells expressing
mutated Ha-ras at high level (Arends, M.J.: unpublished
observations). It is convenient to designate as primed those
cells in which synthesis of the effector proteins of apoptosis
has been induced, and so to distinguish them both from the
unprimed cells that lack effectors and cannot immediately
undergo apoptosis, and from cells in the process of entering
apoptosis through activation of the effectors, which we call
triggered (Arends & Wyllie, 1991). The concept that genes
regulate dynamic transitions between suseptibility and resis-
tance to apoptosis has important implications for our under-
standing of regulation of normal tissue kinetics and several
aspects of the behaviour of tumour cells.
Thus, during affinity maturation of the immune response,
virgin circulating B cells enter the follicle centre and are
stimulated by local factors to rapid cell proliferation. How-
ever, the majority of these cells are destined for almost
immediate death by apoptosis: they are in the high turnover
state described previously complete with high c-myc expres-
sion. Only a small sub-population is selected for long-term
survival (and B-cell memory) on the basis of the affinity of
their surface immunoglobulin for the antigen, presented on
the surface of dendritic cells in the follicle centre (Liu et al.,
1989). This 'rescue' is associated with induction of bcl-2 in
the surviving cells (Nunez et al., 1991; Hockenberry et al.,
1991).
Although much less is known of the gene expression
involved, an analogous situation exists in development of the
nervous system. Motor neurones are generated in excess of
eventual requirement, and deleted by apoptosis if their axons
fail to make contact with muscle endplates, the source of
growth factors which presumably rescue them from death.
Rather similar processes appear to take place in the central
nervous system in development of glia and the establishment
of interneuronal networks in the central nervous system
(Martin et al., 1988; Raff, 1992).
One corollary of the hypotheses outlined above is that cells
in the high turnover state include many that are primed for
apoptosis and therefore susceptible to die by this means in
response to a variety of lethal stimuli. Cells of the lymphoid
follicle centre phenotype and at the base of intestinal crypts
(another high-turnover, c-myc-expressing, bcl-2 expressing
population) (Liu et al., 1989; Nunez et al., 1991) are indeed
susceptible to apoptosis engendered by agents with widely
divergent modes of action (including many used in cancer
chemotherapy) (Ijiri & Potten, 1987). There are obvious im-
plications for toxicology and cancer chemotherapy if cell
sensitivity to apoptosis can be modified by manipulation of a
set of regulatory genes.
Similarly, there are implications in carcinogenesis. The
genes discussed above as influencing apoptosis are all
familiar because of their abnormal regulation in neoplasms.
One important element in the early phases of carcinogenesis
may be expansion of a target population of cells capable of
subsequent genetic progression to malignancy, perhaps as aAPOFTOSIS 207
result of further genetic events. This target population may
normally be kept small through apoptosis. Inappropriate
rescuing stimuli may therefore be oncogenic simply because
they increase the number of cells available for mutagenesis.
There are several potential examples, such as ras expression
in premalignant hyperplasias of breast (Going et al., 1992)
and in colorectal adenomas (Williams et al., 1985) and the
constitutive bcl-2 expression of follicular lymphomas and the
LMP-l-induced bcl-2 expression of drug-resistant Burkitt's
lymphoma cell lines (Clark et al., 1992; Gregory et al., 1991;
Henderson et al., 1991).
The pervasiveness of p53 mutation in human malignancies
(Levine et al., 1991) may be accounted for in a similar way.
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